#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

In vitro and molecular chemosensitivity in human cholangiocarcinoma tissues


Autoři: Manida Suksawat aff001;  Poramate Klanrit aff001;  Jutarop Phetcharaburanin aff001;  Nisana Namwat aff001;  Narong Khuntikeo aff002;  Attapol Titapun aff002;  Apiwat Jarearnrat aff002;  Prakasit Sa-ngiamwibool aff002;  Anchalee Techasen aff002;  Watcharin Loilome aff001
Působiště autorů: Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand aff001;  Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen, Thailand aff002;  Cholangiocarcinoma Screening and Care Program (CASCAP), Khon Kaen University, Khon Kaen, Thailand aff003;  Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand aff004;  Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand aff005;  Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand aff006
Vyšlo v časopise: PLoS ONE 14(9)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0222140

Souhrn

Adjuvant chemotherapy is required for cholangiocarcinoma (CCA) patients after surgical treatment. Gemcitabine and gemcitabine plus cisplatin are considered the appropriate regimen; however, the response spectrum to chemotherapy differs between patients. Thus, the present study aims to evaluate the response pattern of individual CCA patients by using an in vitro method, histoculture drug response assay (HDRA), to predict the chemosensitivity of individual patients in a prospective study. Moreover, we also investigate the expression of gemcitabine and cisplatin sensitivity factors in CCA tissues in the same cases. Based on the dose response curve, 1000 and 1500 μg/ml of gemcitabine were used as the testing concentrations. For cisplatin, concentrations of 20 and 25 μg/ml were selected for testing and for the combination regimen, 1000 μg/ml of gemcitabine and 20 μg/ml of cisplatin were chosen. The median %IR of each drug was measured as the cut-off to categorize the response pattern into response and non-response groups. In addition, we compared the effectiveness of the chemotherapy regimens between gemcitabine alone and gemcitabine plus cisplatin. The %IR of the combination of gemcitabine and cisplatin was significantly higher than gemcitabine alone. The relationship between the expression level of gemcitabine and cisplatin sensitive factors and the individual response pattern as well as clinicopathological data of CCA patients were analyzed. The results indicated that a low expression of the gemcitabine sensitive factor hENT-1 was significantly associated with the non-response group in vitro (p = 0.002). Moreover, the low expression of hENT-1 was also significantly associated with advanced stages CCA in the patients (p = 0.025). A low expression of MT and ERCC1 was significantly correlated with the response group in the in vitro experiments (p = 0.015 and p = 0.037 for MT and ERCC1, respectively). Therefore, HDRA may serve as an aid to selecting chemotherapy, and the expression of hNET-1, MT and ERCC1 may serve as biomarkers for predicting chemotherapy success.

Klíčová slova:

Biology and life sciences – Biochemistry – Biomarkers – Molecular biology – Molecular biology techniques – Molecular biology assays and analysis techniques – Gene expression and vector techniques – Protein expression – Medicine and health sciences – Oncology – Cancer treatment – Cancer chemotherapy – Clinical oncology – Metastasis – Basic cancer research – Oncology agents – Chemotherapeutic agents – Cancers and neoplasms – Carcinomas – Adenocarcinomas – Cholangiocarcinoma – Gastrointestinal tumors – Pharmaceutics – Drug therapy – Chemotherapy – Clinical medicine – Pharmacology – Drugs – Surgical and invasive medical procedures – Research and analysis methods – Histochemistry and cytochemistry techniques – Immunohistochemistry techniques – Immunologic techniques


Zdroje

1. Vatanasapt V, Sriamporn S, Vatanasapt P. Cancer control in Thailand. Japanese journal of clinical oncology. 2002;32 Suppl:S82–91. doi: 10.1093/jjco/hye134 11959881

2. Titapun A, Pugkhem A, Luvira V, Srisuk T, Somintara O, Saeseow OT, et al. Outcome of curative resection for perihilar cholangiocarcinoma in Northeast Thailand. World journal of gastrointestinal oncology. 2015;7(12):503–12. doi: 10.4251/wjgo.v7.i12.503 26691730

3. Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World journal of gastroenterology. 2009;15(34):4240–62. doi: 10.3748/wjg.15.4240 19750567

4. Wirasorn K, Ngamprasertchai T, Khuntikeo N, Pakkhem A, Ungarereevittaya P, Chindaprasirt J, et al. Adjuvant chemotherapy in resectable cholangiocarcinoma patients. Journal of gastroenterology and hepatology. 2013;28(12):1885–91. doi: 10.1111/jgh.12321 23829232

5. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. The New England journal of medicine. 2010;362(14):1273–81. doi: 10.1056/NEJMoa0908721 20375404

6. Roden DM, George AL Jr. The genetic basis of variability in drug responses. Nature reviews Drug discovery. 2002;1(1):37–44. doi: 10.1038/nrd705 12119608

7. Hoffman RM. In vitro sensitivity assays in cancer: a review, analysis, and prognosis. Journal of clinical laboratory analysis. 1991;5(2):133–43. doi: 10.1002/jcla.1860050211 2023059

8. Sherwin RP, Richters A, Yellin AE, Donovan AJ. Histoculture of human breast cancers. Journal of surgical oncology. 1980;13(1):9–20. doi: 10.1002/jso.2930130103 6243380

9. Lee SW, Kim YM, Kim MB, Kim DY, Kim JH, Nam JH, et al. In vitro chemosensitivity using the histoculture drug response assay in human epithelial ovarian cancer. Acta medica Okayama. 2012;66(3):271–7. doi: 10.18926/AMO/48567 22729108

10. Shinden Y, Kijima Y, Hirata M, Arima H, Nakajyo A, Tanoue K, et al. Clinical Significance of the Histoculture Drug Response Assay in Breast Cancer. Anticancer research. 2016;36(11):6173–8. doi: 10.21873/anticanres.11210 27793948

11. Furukawa T, Kubota T, Tanino H, Oura S, Yuasa S, Murate H, et al. Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay. Anticancer research. 2000;20(5C):3657–8. 11268434

12. Voutsadakis IA. Molecular predictors of gemcitabine response in pancreatic cancer. World journal of gastrointestinal oncology. 2011;3(11):153–64. doi: 10.4251/wjgo.v3.i11.153 22110842

13. Binenbaum Y, Na'ara S, Gil Z. Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. 2015;23:55–68. doi: 10.1016/j.drup.2015.10.002 26690340

14. Kroep JR, Loves WJ, van der Wilt CL, Alvarez E, Talianidis I, Boven E, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Molecular cancer therapeutics. 2002;1(6):371–6. 12477049

15. Deng T, Pan H, Han R, Huang D, Li H, Zhou L, et al. Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer. International journal of clinical and experimental medicine. 2014;7(12):5041–9. 25664003

16. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006;24(29):4731–7. doi: 10.1200/JCO.2006.06.1101 16966686

17. Surowiak P, Materna V, Maciejczyk A, Pudelko M, Markwitz E, Spaczynski M, et al. Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Archiv: an international journal of pathology. 2007;450(3):279–85. doi: 10.1007/s00428-006-0362-7 17235562

18. Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. British journal of cancer. 2008;99(1):167–72. doi: 10.1038/sj.bjc.6604464 18594541

19. Suksawat M, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, Titapun A, et al. Upregulation of endothelial nitric oxide synthase (eNOS) and its upstream regulators in Opisthorchis viverrini associated cholangiocarcinoma and its clinical significance. Parasitology international. 2017;66(4):486–93. doi: 10.1016/j.parint.2016.04.008 27143607

20. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. Jama. 2001;286(18):2270–9. doi: 10.1001/jama.286.18.2270 11710893

21. Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, et al. Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clinical cancer research: an official journal of the American Association for Cancer Research. 1995;1(12):1537–43. 9815954

22. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clinical cancer research: an official journal of the American Association for Cancer Research. 1995;1(3):305–11. 9815986

23. Fujita Y, Hiramatsu M, Kawai M, Nishimura H, Miyamoto A, Tanigawa N. Histoculture drug response assay predicts the postoperative prognosis of patients with esophageal cancer. Oncology reports. 2009;21(2):499–505. 19148528

24. Yoshimasu T, Oura S, Hirai I, Tamaki T, Kokawa Y, Hata K, et al. Data acquisition for the histoculture drug response assay in lung cancer. The Journal of thoracic and cardiovascular surgery. 2007;133(2):303–8. doi: 10.1016/j.jtcvs.2006.06.030 17258552

25. Sookprasert A. Role of Systemic Chemotherapy in Advanced Cholangiocarcinoma. Srinagarind Med J 2012;27:5.

26. Wattanawongdon W, Hahnvajanawong C, Namwat N, Kanchanawat S, Boonmars T, Jearanaikoon P, et al. Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. International journal of oncology. 2015;47(1):398–410. doi: 10.3892/ijo.2015.3019 25998688

27. Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. Journal of the National Cancer Institute. 2014;106(1):djt347. doi: 10.1093/jnci/djt347 24301456

28. Sasaki H, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, et al. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy. British journal of cancer. 2014;111(7):1275–84. doi: 10.1038/bjc.2014.399 25032731

29. Tuzel E, Yorukoglu K, Ozkara E, Kirkali Z. Association of metallothionein expression and clinical response to cisplatin based chemotherapy in testicular germ cell tumors. Central European journal of urology. 2015;68(1):45–50. doi: 10.5173/ceju.2015.01.486 25914837

30. Wood DP Jr., Klein E, Fair WR, Chaganti RS. Metallothionein gene expression in bladder cancer exposed to cisplatin. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 1993;6(1):33–5. 8426855

31. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1998;16(1):309–16. doi: 10.1200/JCO.1998.16.1.309 9440758

32. Marin JJG, Lozano E, Herraez E, Asensio M, Di Giacomo S, Romero MR, et al. Chemoresistance and chemosensitization in cholangiocarcinoma. Biochimica et biophysica acta Molecular basis of disease. 2018;1864(4 Pt B):1444–53. doi: 10.1016/j.bbadis.2017.06.005 28600147


Článek vyšel v časopise

PLOS One


2019 Číslo 9
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

plice
INSIGHTS from European Respiratory Congress
nový kurz

Současné pohledy na riziko v parodontologii
Autoři: MUDr. Ladislav Korábek, CSc., MBA

Svět praktické medicíny 3/2024 (znalostní test z časopisu)

Kardiologické projevy hypereozinofilií
Autoři: prof. MUDr. Petr Němec, Ph.D.

Střevní příprava před kolonoskopií
Autoři: MUDr. Klára Kmochová, Ph.D.

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#